pharma · TTR-mediated Amyloidosis · Hypertension · ALNY
Alnylam Netherlands
Alnylam Netherlands B.V.
Alnylam Netherlands clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2002
- Employees
- 2,826
- Programs
- 84
- Drugs
- 37
- Patents
- 379
Alnylam Netherlands projects
21 ClinicalTrials.gov programs sponsored by Alnylam Netherlands.
Alnylam Netherlands has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ALN-AGT01-008
Alnylam Netherlands B.V.
High cardiovascular risk, Established cardiovascular disease, Hypertension
1 trial -
ALN-TTR02-011
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
ALN-TTRSC02-002
Alnylam Netherlands B.V.
Hereditary Transthyretin Amyloidosis
1 trial -
ALN-TTRSC02-003
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
ALN-TTRSC04-004
Alnylam Netherlands B.V.
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
1 trial -
Amvuttra 25 mg solution for injection in pre-filled syringe
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
Givosiran
Alnylam Netherlands B.V.
Acute Hepatic Porphyria
1 trial -
Lumasiran
Alnylam Netherlands B.V.
Primary Hyperoxaluria
1 trial -
Lumasiran
Alnylam Netherlands B.V.
Primary Hyperoxaluria Type 1
1 trial -
Nucresiran
Alnylam Netherlands B.V.
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
1 trial -
Nucresiran
Alnylam Netherlands B.V.
Transthyretin Amyloidosis With Cardiomyopathy
1 trial -
Patisiran
Alnylam Netherlands B.V.
Amyloidosis, Hereditary
1 trial -
Patisiran
Alnylam Netherlands B.V.
Amyloidosis, Familial
1 trial -
Patisiran
Alnylam Netherlands B.V.
Amyloidosis
1 trial -
Placebo
Alnylam Netherlands B.V.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
1 trial -
Placebo
Alnylam Netherlands B.V.
Primary Hyperoxaluria Type 1 (PH1)
1 trial -
Placebo for Nucresiran, ALN-TTRSC04
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
Revusiran (ALN-TTRSC)
Alnylam Netherlands B.V.
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
1 trial -
Vutrisiran
Alnylam Netherlands B.V.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
2 trials -
Zilebesiran
Alnylam Netherlands B.V.
High Risk Cardiovascular Disease
1 trial -
patisiran (ALN-TTR02)
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial
Frequently asked questions
How many clinical projects does Alnylam Netherlands have?
21 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.